CL2011001879A1 - Compuestos derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles, inhibidores de met; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de enfermedades tales como trastornos de la proliferacion de vasos sanguineos, asmas, artritis reumatoide y cancer. - Google Patents

Compuestos derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles, inhibidores de met; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de enfermedades tales como trastornos de la proliferacion de vasos sanguineos, asmas, artritis reumatoide y cancer.

Info

Publication number: CL2011001879A1
Authority: CL; Chile
Prior art keywords: triazolopyridazine; benzothiazoles; benzimidazoles; sulfanyl; asthma
Prior art date: 2009-02-06

Application number

CL2011001879A

Other languages

English (en)

Spanish (es)

Inventor

Sylvie Wentzler

Antonio Ugolini

Dominique Damour

Concepcion Nemceck

Eric Bacque

Gilles Barbalat

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-06

Filing date

2011-08-04

Publication date

2012-01-06

2011-08-04 Application filed by Sanofi Sa filed Critical Sanofi Sa

2012-01-06 Publication of CL2011001879A1 publication Critical patent/CL2011001879A1/es

Links

125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 title abstract 2
208000006673 asthma Diseases 0.000 title abstract 2
150000001556 benzimidazoles Chemical class 0.000 title abstract 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title abstract 2
210000004204 blood vessel Anatomy 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title abstract 2
230000006806 disease prevention Effects 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
208000035475 disorder Diseases 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
230000035755 proliferation Effects 0.000 title abstract 2
206010039073 rheumatoid arthritis Diseases 0.000 title abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Oncology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2011001879A 2009-02-06 2011-08-04 Compuestos derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles, inhibidores de met; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de enfermedades tales como trastornos de la proliferacion de vasos sanguineos, asmas, artritis reumatoide y cancer. CL2011001879A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0900512A FR2941950B1 (fr)	2009-02-06	2009-02-06	Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Publications (1)

Publication Number	Publication Date
CL2011001879A1 true CL2011001879A1 (es)	2012-01-06

Family

ID=40872767

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2011001879A CL2011001879A1 (es)	2009-02-06	2011-08-04	Compuestos derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles, inhibidores de met; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de enfermedades tales como trastornos de la proliferacion de vasos sanguineos, asmas, artritis reumatoide y cancer.

Country Status (19)

Country	Link
EP (1)	EP2393791A1 (pt)
JP (1)	JP2012517408A (pt)
KR (1)	KR20110132560A (pt)
CN (1)	CN102378759A (pt)
AR (1)	AR075249A1 (pt)
AU (1)	AU2010212232A1 (pt)
BR (1)	BRPI1008232A2 (pt)
CA (1)	CA2750875A1 (pt)
CL (1)	CL2011001879A1 (pt)
CO (1)	CO6400223A2 (pt)
EA (1)	EA201171011A1 (pt)
FR (1)	FR2941950B1 (pt)
IL (1)	IL214406A0 (pt)
MA (1)	MA33107B1 (pt)
MX (1)	MX2011008319A (pt)
SG (1)	SG173559A1 (pt)
TW (1)	TW201031670A (pt)
UY (1)	UY32420A (pt)
WO (1)	WO2010089507A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA026655B1 (ru)	2011-09-15	2017-05-31	Новартис Аг	6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
US9586963B2 (en) *	2011-09-27	2017-03-07	Genfit	Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
GB201321745D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
EP4687905A1 (en)	2023-03-30	2026-02-11	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en)	2023-05-04	2025-12-11	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
IL326136A (en)	2023-08-07	2026-03-01	Revolution Medicines Inc	RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en)	2023-10-12	2025-05-15	Revolution Medicines, Inc.	Ras inhibitors
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
US20250375445A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026050446A1 (en)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Ras inhibitors
WO2026072904A2 (en)	2024-09-26	2026-04-02	Revolution Medicines, Inc.	Compositions and methods for treating lung cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1298125A1 (en)	2001-09-26	2003-04-02	Aventis Pharma S.A.	Substituted benzimidazole compounds and their use for the treatment of cancer
KR20080080584A (ko) *	2005-11-30	2008-09-04	버텍스 파마슈티칼스 인코포레이티드	ｃ-Ｍｅｔ의 억제제 및 이의 용도
HUE030390T2 (en) *	2005-12-21	2017-05-29	Janssen Pharmaceutica Nv	Triazolopyridazines as tyrosine kinase modulators
JP2009538899A (ja) *	2006-05-30	2009-11-12	ファイザー・プロダクツ・インク	トリアゾロピリダジン誘導体
PE20080403A1 (es) *	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
AU2007309149C1 (en) *	2006-10-23	2013-04-04	Sgx Pharmaceuticals, Inc.	Bicyclic triazoles as protein kinase modulators
PA8792501A1 (es) *	2007-08-09	2009-04-23	Sanofi Aventis	Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.

2009
- 2009-02-06 FR FR0900512A patent/FR2941950B1/fr not_active Expired - Fee Related
2010
- 2010-02-04 CA CA2750875A patent/CA2750875A1/fr not_active Abandoned
- 2010-02-04 MX MX2011008319A patent/MX2011008319A/es not_active Application Discontinuation
- 2010-02-04 MA MA34152A patent/MA33107B1/fr unknown
- 2010-02-04 EA EA201171011A patent/EA201171011A1/ru unknown
- 2010-02-04 EP EP10708278A patent/EP2393791A1/fr not_active Withdrawn
- 2010-02-04 CN CN2010800155375A patent/CN102378759A/zh active Pending
- 2010-02-04 KR KR1020117020677A patent/KR20110132560A/ko not_active Withdrawn
- 2010-02-04 JP JP2011548751A patent/JP2012517408A/ja not_active Withdrawn
- 2010-02-04 SG SG2011056488A patent/SG173559A1/en unknown
- 2010-02-04 WO PCT/FR2010/050178 patent/WO2010089507A1/fr not_active Ceased
- 2010-02-04 BR BRPI1008232A patent/BRPI1008232A2/pt not_active IP Right Cessation
- 2010-02-04 AU AU2010212232A patent/AU2010212232A1/en not_active Abandoned
- 2010-02-05 AR ARP100100317A patent/AR075249A1/es unknown
- 2010-02-05 UY UY0001032420A patent/UY32420A/es not_active Application Discontinuation
- 2010-02-05 TW TW099103579A patent/TW201031670A/zh unknown
2011
- 2011-08-02 IL IL214406A patent/IL214406A0/en unknown
- 2011-08-04 CL CL2011001879A patent/CL2011001879A1/es unknown
- 2011-08-05 CO CO11099127A patent/CO6400223A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2010089507A1 (fr)	2010-08-12
UY32420A (es)	2010-09-30
EA201171011A1 (ru)	2012-03-30
IL214406A0 (en)	2011-09-27
FR2941950A1 (fr)	2010-08-13
MA33107B1 (fr)	2012-03-01
MX2011008319A (es)	2012-01-25
CA2750875A1 (fr)	2010-08-12
AR075249A1 (es)	2011-03-16
BRPI1008232A2 (pt)	2016-03-08
CN102378759A (zh)	2012-03-14
EP2393791A1 (fr)	2011-12-14
FR2941950B1 (fr)	2011-04-01
CO6400223A2 (es)	2012-03-15
JP2012517408A (ja)	2012-08-02
TW201031670A (en)	2010-09-01
AU2010212232A1 (en)	2011-08-25
SG173559A1 (en)	2011-09-29
KR20110132560A (ko)	2011-12-08

Publication	Publication Date	Title
CL2011001879A1 (es)	2012-01-06	Compuestos derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles, inhibidores de met; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de enfermedades tales como trastornos de la proliferacion de vasos sanguineos, asmas, artritis reumatoide y cancer.
CL2010001641A1 (es)	2011-07-15	Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras.
PH12013500299B1 (en)	2019-03-08	Pyrrolopyrimidine compounds and uses thereof
CL2013000016A1 (es)	2013-04-19	Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2012001627A1 (es)	2012-10-05	Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
CL2014001547A1 (es)	2014-10-24	Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CL2012000163A1 (es)	2012-07-13	Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
ECSP14013325A (es)	2015-04-30	Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr)
CO6511228A2 (es)	2012-08-31	(heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
CL2012001073A1 (es)	2012-10-26	Compuestos derivados de pirido[4,3-d]pirimidin-5-ona, sus composiciones farmaceuticas y su uso como inhibidores de quinasa para tratar asma, epoc, colitis ulcerante, bronquitis, lupus, cancer de mamas, enfermedad de alzheimer, enfermedad de parkinson, osteoporosis, esclerosis multiple, diabetes, trastornos oculares, restenosis, enfermedades inflamatorias.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2011001299A1 (es)	2012-01-13	Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer.
CL2012002497A1 (es)	2013-03-22	Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
NZ719905A (en)	2019-10-25	Bicyclic heterocycle compounds and their uses in therapy
CL2011002942A1 (es)	2012-04-13	Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2009000650A1 (es)	2010-03-26	Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CL2012003722A1 (es)	2014-03-21	Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
AR082340A1 (es)	2012-11-28	Metodos y composiciones para la terapia del cancer de higado
CL2008001632A1 (es)	2009-10-16	Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
DOP2013000192A (es)	2014-01-31	Compuestos y composiciones como inhibidores de la trk
IN2012MN02591A (pt)	2015-06-12
CL2012001405A1 (es)	2012-09-28	Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
SMT201400148B (it)	2015-01-15	Inibitori di jak2 e loro uso per il trattamento del cancro e di malattie mieloproliferative
CL2007003774A1 (es)	2008-04-18	Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
SMT201600055B (it)	2016-04-29	Composizione farmaceutica per il trattamento o la prevenzione del glaucoma